cyclophosphamide

Allogeneic hematopoietic stem cell transplantation (HSCT) is considered standard of care in eligible patients with acute myeloid leukemia (AML) and intermediate or adverse risk in first complete remission (CR) as …

Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48. Article  PubMed  PubMed Central  Google …

Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273–82. https://doi.org/10.1182/blood.2021011281. …

Patient characteristics Baseline characteristics of the study population are shown in Table 1. A total of 8,764 patients were included, of whom 7,725 (88%) received his rATG and 1,039 (12%) …